non-small-cell lung cancer

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. 

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc. 

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

• Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
• The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
• The HER2xHER3 bispecific antibody zenocutuzumab
• The HER3-targeted antibody–drug conjugate SHR-A2009 

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc. 

Link to full program, including a downloadable highlights slideset: 
https://bit.ly/48ecElW

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc. 

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

• Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
• Second-line therapeutic options after disease progression on an immunotherapy-based regimen
• Immunotherapy in patients with advanced NSCLC and brain metastases
• Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
• Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response

Presenters:

Julie Brahmer, MD, MSc
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.

Follow along with the PDF:
https://bit.ly/31aRRmd

Link to full program:
https://bit.ly/3CLC0Hd

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

• Mechanisms of acquired resistance to TRK inhibitor therapy
• Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
• Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

• Basket trials leading to FDA approvals of larotrectinib and entrectinib
• Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
• Sequencing treatment with TRK inhibition in patients with solid tumors
• Clinically relevant similarities and differences between larotrectinib and entrectinib

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slidesets:
https://bit.ly/2YFIPfr

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:

• Differences between NTRK fusions vs gene mutations
• Frequency of NTRK fusions by age and tumor type
• When to test patients for NTRK fusions and interpreting reports
• Methods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsy

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program:
https://bit.ly/2YFIPfr

Link to slideset based on this podcast:
https://bit.ly/3amgU6w

The Oncology Journal Club - Delivering Oncology News Differently

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 47 in our series The Oncology Journal Club.

This week Eva Segelov talks us through a practice changing paper on the duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. Craig Underhill looks at the KEYNOTE-598 study on metastatic non-small-cell lung cancer aaaaand Hans Prenen is back! He tackles the therapeutic implications of germline testing in advanced cancers.

Quick bites are as diverse as ever covering the NeoSCOPE trial, text messaging, cancer misinformation and fake news, conflicts of interest, liquid biopsies and much more.

As ever, you’ll find links to all the papers, bios and twitter handles in the notes on our website.

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

Full bios and the list of all papers discussed are available on our website.

For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.

The Oncology Podcast - An Australian Oncology Perspective

Welcome to the Thoracic Oncology Group of Australasia Podcast series. 

This TOGA Podcast focuses on thriving with lung cancer and overcoming the challenges associated with long term survivorship and lung cancer. The past decade has seen significant advances in the management of metastatic NSCLC with the advent of multiple targeted therapies, immunotherapy approaches and combination approaches and associated improvements in survival outcomes for patients. There is an emerging cohort of patients with advanced NSCLC who experience long periods of disease control whilst on these treatments. 

Traditionally survivorship has referred to the care of or issues for patients following curative treatment of early-stage disease. However, due to the recent advances described here, there is a compelling need to begin addressing the issues faced by long term metastatic disease ’survivors’. 

In this Podcast, we welcome Lillian Leigh, a long-term survivor of lung cancer, Dr Sarah Heynemann, Oncology Fellow from the Chris O’Brien Lifehouse and Mary Duffy, Lung Cancer Clinical Nurse Consultant (CNC) in the Lung MDT at Peter MacCallum Cancer Institute about the issue’s patients face and how to support long term survivors of lung cancer.

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:

• Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC
• Incorporating newly approved immunotherapies into practice
• Evolving guidelines and recommendations for biomarker testing  
• RNA- vs DNA-based next-generation sequencing
• Interpretation of NGS results
• Use of frontline TKI therapy for patients with CNS metastases
• Future role of KRAS inhibitors in the treatment of advanced NSCLC
• Improving rates of biomarker testing in lung cancer

Presenters:

Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen V. Liu, MD
Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Supported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3npjyyb

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

• Optimal testing for RET fusions
• DNA NGS vs RNA NGS
• Molecular testing workflows
• Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
• Common toxicities with new selective RET inhibitors
• Interdisciplinary communication between medical oncologists and pathologists

Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:

• Incorporating MET exon 14 testing into standard of care
• Comparison of RNA-based and DNA-based NGS platforms
• Availability of RNA-based NGS testing around the world
• Using FISH to quantify MET copy gain/amplification
• Regulatory and clinical differences between new, selective MET inhibitors
• Safety profiles of type I vs type II MET inhibitors
• Counseling patients on management of peripheral edema, a class effect with MET inhibitor therapy
• Insights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapy
• Selecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinib

Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Content based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

Link to full program, including associated downloadable slidesets:
https://bit.ly/2ExadCf

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:

• Whether testing for MET  exon 14 status should be standard of care
• Parallel vs sequential testing by DNA-based vs RNA-based NGS
• Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC
• Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy
• EMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinib

Presenters:
Luis Paz-Ares, MD, PhD 
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Link to full program, including associated downloadable slidesets:  https://bit.ly/2ExadCf

The Oncology Journal Club - Delivering Oncology News Differently

The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode in our new series - The Oncology Journal Club.

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and studies presented at key meetings to help keep you informed of the latest developments on the go.

Today's episode is presented by Professor Eva Segelov, joined by Dr Craig Underhill and Professor Hans Prenen. Full bios and the list of all papers discussed are available on our website.

For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

The Oncology Podcast - An Australian Oncology Perspective